Skip to main content
Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study

Fig. 4

Mean change in patient-reported outcome scores by Psoriatic Arthritis Disease Activity Score (PASDAS) states at weeks 16, 52 and 104. Data are from mixed model for repeated measures analysis. *P < 0.0001; †P < 0.001; §P < 0.01; ‡P < 0.05 versus HDA. n = number of patients with measurements at baseline and post-baseline visits; N = number of patients in each group of the specified analysis set. DLQI Dermatology Life Quality Index, FACIT-Fatigue Functional Assessment of Chronic Illness Therapy–Fatigue, HAQ-DI Health Assessment Questionnaire Disability Index, HDA High disease activity, LDA Low disease activity, LS Least squares, PsAQoL Psoriatic arthritis-specific quality of life, SF-36 MCS Short Form Health Survey Mental Component Summary, SF-36 PCS Short Form Health Survey Physical Component Summary. Week 16: N = 32 (remission), N = 53 (LDA), N = 128 (MoDA) and N = 69 (HDA); week 52: N = 44 (remission), N = 81 (LDA), N = 112 (MoDA) and N = 21 (HDA); week 104: N = 47 (remission), N = 81 (LDA), N = 95 (MoDA) and N = 13 (HDA). Analytic data were pooled across treatment arms

Back to article page